Whole Genome Sequencing of Waldenstrom's Macroglobulinemia

Whole genome sequencing was conducted on 10 tumor/germline paired samples along with 20 additional unpaired tumor samples from patients with Waldesntrom's macroglobulinemia. Tumor lymphoplasmacytic lymphoma cells were obtained from CD19+ selected bone marrow mononuclear cells. Germline tissue was obtained from CD19 depleted peripheral blood mononuclear cells. High molecular weight DNA was then submitted for whole genome sequencing with Complete Genomics and aligned to HG19/NCBI human reference build 37.]]>
All participants had to have given consent to sample collection in accordance with the Dana-Farber Cancer Institute Institutional Review Board and received a clinicopathological diagnosis of WM as defined by the Second International Workshop on WM.]]>

本研究对10例华氏巨球蛋白血症（Waldenström's Macroglobulinemia，以下简称WM）患者的10份肿瘤/生殖细胞配对样本，以及额外20份未配对肿瘤样本开展全基因组测序。肿瘤性淋巴浆细胞淋巴瘤细胞通过CD19阳性分选骨髓单个核细胞分离获得；生殖细胞组织则取自CD19耗竭的外周血单个核细胞。随后将提取的高分子量DNA提交至Complete Genomics平台进行全基因组测序，并将测序序列比对至HG19/NCBI人类参考基因组版本37。所有受试者均已签署样本采集知情同意书，研究工作符合丹娜法伯癌症研究院（Dana-Farber Cancer Institute）伦理审查委员会的相关规范；所有患者均按照第二届国际华氏巨球蛋白血症研讨会制定的临床病理诊断标准确诊为WM。